Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MorphoSys AG (MOR) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (416)	8/13/2013 10:25:09 AM
From: Germanecki	Respond to of 421

MorphoSys Closes on the Alliance with Celgene for MOR202 and Increases Financial Guidance August 10, 2013 / 8:59 am, CET Celgene Acquires 3.4 % Equity Stake via a Capital Increase MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that its MOR202 alliance with Celgene Corporation has become effective upon receiving anti-trust clearance under the US Hart-Scott-Rodino Act. In conjunction with deal closure, MorphoSys increased its financial guidance for fiscal year 2013 and the management board and supervisory board of MorphoSys resolved on a capital increase from authorized capital to issue 797,150 new shares to Celgene Alpine Investment Co., LLC. Jens Holstein, Chief Financial Officer of MorphoSys AG, commented: "We are very pleased about receiving regulatory clearance and will now put our strategic alliance with Celgene into action. The upfront payment plus the equity further strengthens our financial position, enabling us to expand our proprietary portfolio of promising development candidates through targeted investments". As a result of the Celgene transaction, MorphoSys has increased its financial guidance for fiscal year 2013. MorphoSys now expects revenues of approximately EUR 74 million to EUR 78 million (previously EUR 68 million to EUR 72 million) and an EBIT of EUR 2 million to EUR 6 million (previously EUR -2 million to EUR +2 million). In the capital increase Celgene will invest EUR 46.2 million to subscribe for 797,150 new shares of MorphoSys at a share price of EUR 57.90 per share. This represents 3.4 % of MorphoSys's registered share capital and a premium of 5.0 % on the share's closing price on August 9, 2013. About MorphoSys: ..... morphosys.com